信立泰(002294.SZ)：SAL0140药品临床试验申请获得受理

Core Viewpoint - The company, Shenzhen Sinopharm Holdings, has received approval from the National Medical Products Administration for the clinical trial application of its innovative small molecule drug SAL0140, which targets uncontrolled hypertension and chronic kidney disease [1] Group 1: Company Information - Shenzhen Sinopharm Holdings has developed SAL0140, a novel aldosterone synthase inhibitor with proprietary intellectual property [1] - The drug is currently in Phase I clinical trials for the indication of uncontrolled hypertension [1] Group 2: Industry Context - SAL0140 is aimed at treating conditions such as resistant hypertension and chronic kidney disease (CKD), which are significant health concerns [1]